This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Humanigen マネジメント
マネジメント 基準チェック /24
現在、CEO に関する十分な情報がありません。
主要情報
Cameron Durrant
最高経営責任者
n/a
報酬総額
| CEO給与比率 | n/a |
| CEO在任期間 | 8.3yrs |
| CEOの所有権 | n/a |
| 経営陣の平均在職期間 | データなし |
| 取締役会の平均在任期間 | 7.5yrs |
経営陣の近況
Recent updates
Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M
Aug 12Humanigen plunges 57% as trial for COVID-19 therapy fails
Jul 13Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy
Jul 06Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30
Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.
Jun 14Humanigen submits lenzilumab COVID-19 EUA application to FDA
May 28Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 05Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price
May 05We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon
Mar 31Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?
Feb 26Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19
Jan 29Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment
Jan 11We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04
Humanigen secures new U.S. patent for lenzilumab
Dec 28Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme
Dec 17Humanigen EPS misses by $0.16
Nov 11Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19
Nov 06Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Nov 03Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 01Dosing underway in lenzilumab late-stage study in COVID-19
Oct 30Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19
Oct 29CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$54m |
| Dec 31 2022 | US$1m | US$640k | -US$71m |
| Sep 30 2022 | n/a | n/a | -US$109m |
| Jun 30 2022 | n/a | n/a | -US$152m |
| Mar 31 2022 | n/a | n/a | -US$192m |
| Dec 31 2021 | US$10m | US$640k | -US$237m |
| Sep 30 2021 | n/a | n/a | -US$235m |
| Jun 30 2021 | n/a | n/a | -US$199m |
| Mar 31 2021 | n/a | n/a | -US$153m |
| Dec 31 2020 | US$2m | US$600k | -US$90m |
| Sep 30 2020 | n/a | n/a | -US$59m |
| Jun 30 2020 | n/a | n/a | -US$31m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | US$785k | US$600k | -US$10m |
| Sep 30 2019 | n/a | n/a | -US$10m |
| Jun 30 2019 | n/a | n/a | -US$10m |
| Mar 31 2019 | n/a | n/a | -US$9m |
| Dec 31 2018 | US$4m | US$600k | -US$12m |
| Sep 30 2018 | n/a | n/a | -US$13m |
| Jun 30 2018 | n/a | n/a | -US$18m |
| Mar 31 2018 | n/a | n/a | -US$22m |
| Dec 31 2017 | US$790k | US$600k | -US$22m |
報酬と市場: Cameronの 総報酬 がUS市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。
報酬と収益: Cameronの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Cameron Durrant (64 yo)
8.3yrs
在職期間
US$1,099,058
報酬
Dr. Cameron Durrant, MD, MBA, DRCOG, DIPCH, MRCGP, FLSW, has been Chairman of Humanigen, Inc. since January 2016. Dr. Durrant has been Chief Executive Officer at Humanigen, Inc. since March 2016 and has be...
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman | 8.5yrs | US$1.10m | データなし | |
| Chief Scientific Officer & Director | 3.4yrs | US$661.96k | 0% $ 0 | |
| Independent Director | 6.4yrs | US$81.20k | 0.071% $ 0.08 | |
| Independent Director | 8.5yrs | US$61.60k | 0.075% $ 0.09 |
7.5yrs
平均在職期間
64yo
平均年齢
経験豊富なボード: HGEN.Qの 取締役会 は 経験豊富 であると考えられます ( 7.5年の平均在任期間)。